Release date: 2014-06-23
Johnson & Johnson (JNJ) announced on June 19 that it has reached 12 new alliances with life science companies and research institutions around the world to explore early innovation in a wide range of therapeutic areas and across the pharmaceutical, medical device, diagnostic, and consumer health sectors. Johnson & Johnson's chief scientific officer and global pharmaceutical chairman Paul Stoffels said that future medical care will be defined by pharmaceutical companies, academic institutions and government departments. The three parties will work together and make full use of existing advantages to try new ways while thinking about the current model. Innovation.
Since its launch more than a year ago, the Johnson & Johnson Innovation Center is working with life science researchers and entrepreneurs around the world to identify exciting early technologies and turn them into patient solutions.
The early collaboration announced today represents the recent R&D alliances of the Innovation Centers in Boston, California, and London, as well as exciting new technologies such as 3D printing for orthopedic trauma and the creation of new brown fat for metabolic diseases. Advancing new sciences in the field of diseases where medical needs are significantly unmet, such as lymphoma, rheumatoid arthritis, prostate cancer, dementia, Alzheimer's disease, diabetes, and insomnia.
Cooperation includes:
1. Use promising new methods to treat cancer:
For lymphomas - Janssen Biotech and JNJ Innovation have partnered with Weill Cornell Medical College to develop a compound that targets a protein that causes lymphoma.
New Immunotherapy for Prostate Cancer - Janssen Biotech and JNJ Innovation have reached an exclusive global mandate with Aduro Biotech to develop new immunotherapies for prostate cancer.
2. Patient-specific 3-D printing for orthopedic needs:
3-D Print Absorbable Implants - DePuy and Johnson & Johnson Innovation and Medical Device Manufacturers Tissue Regeneration Systems (TRS) have partnered to help develop patient-specific, absorbable implants for trauma and orthopedic surgery Large segmental bone defect treatment in school. The partnership will complement DePuy's proprietary technology and market leadership with TRS' 3D printing technology and development expertise. The collaboration also includes opportunities for development in a range of other applications.
3. Advance the progression of Alzheimer's disease and neuroscience:
Speeding up research on Alzheimer's disease - Yangsen's research and development company's neuroscience will collaborate on the UK's Dementias Research Platform (DRP). DRP is an important initiative of the Medical Research Council (MRC) in the UK to accelerate research on dementia through a public-private partnership with six companies and eight leading academic institutions.
Inductive sedation level - Johnson & Johnson's Ethicon Endo-Surgery has teamed up with BrainStem Biometrics to develop a clinical and operational availability for a small, non-invasive medical device sensor, the Tremor Monitor Unit, which is available for acceptance Anesthetized patients, detecting minute eye movements. As a possible biomarker of basal brainstem function, this technology has the potential to distinguish between sedative safety and unsafe levels.
Insomnia - Janssen Pharmaceuticals, Johnson & Johnson Innovation, Yangsen R&D Neuroscience and Minerva Neurosciences collaborate to develop an orexin-2 receptor antagonist MIN-202 for primary and secondary insomnia and other related nerves Treatment of the disease.
Epigenetic Regulation of the Central Nervous System - Johnson & Johnson Development has been involved in Rodin Therapeutics and Johnson & Johnson's A-Series equity investments, and Rodin is committed to discovering epigenetic modulators for cognitive impairment (including Alzheimer's) Treatment).
4. Seeking novel ways to treat diabetes and cardiovascular disease:
Creating new brown fats - Janssen Pharmaceuticals and Johnson & Johnson have partnered with Energesis Pharmaceuticals to identify biological compounds that stimulate the formation of brown fat (BAT) for the treatment of metabolic diseases. Energesis's novel approach takes advantage of recent scientific discoveries in BAT biology to enhance the body's ability to burn stored fat and reduce insulin resistance.
Nutrition-Induction Pathway - Johnson & Johnson Development has been involved in equity investments in Navitor Pharmaceuticals and Johnson & Johnson. Navitor is developing a highly specific mTORC1 regulator that is responsible for the cellular response to available nutrients, including cell growth and function. Navitor is using the core importance of the mTORC1 pathway to develop new therapies for metabolic diseases such as diabetes, as well as autoimmune, musculoskeletal and other diseases.
Remodeling of the heart - Johnson & Johnson Development has been involved in the equity investments of Ascelegen Therapeutics and Johnson & Johnson. Ascelegen is developing novel therapeutically relevant growth factors for cardiovascular disease, including heart failure. Ascelegen's work is based on the GDF-11 study conducted by the Harvard Stem Cell Institute and Brigham-Women Hospital.
5. For autoimmune diseases:
Ending the production of autoantigens in rheumatoid arthritis and other autoimmune diseases - Johnson & Johnson has been involved in the equity investments of Padlock Therapeutics and Johnson & Johnson. Padlock is developing novel therapies targeting the protein arginine deiminase, a class of enzymes that mediate protein citrulline. Protein citrulline can lead to the production of strong autoantigens, participate in the earliest events leading to rheumatoid arthritis, and drive the formation of inflammation and immune complexes of active autoimmune diseases.
6. New strategies in the areas of skin, mouth and respiratory diseases:
Exploring the impact of Microbiome on health and disease – Johnson & Johnson Consumers and Johnson & Johnson have partnered with the University of Manchester to explore the potential of probiotic extracts for the prevention and treatment of skin, mouth and respiratory diseases. The agreement highlights Johnson & Johnson's approach to creating research collaboration across the pharmaceutical, medical device, diagnostic and consumer businesses.
Last year, JNJ Innovation launched its Innovation Center and established four regional hubs to identify scientific opportunities with the potential to advance new healthcare solutions. Through the Innovation Center, external innovators are able to access a wide range of resources within Johnson & Johnson, including funding, research and development expertise and incubation. Currently, offices in Boston, London and California are fully operational. The fourth office in Shanghai , China has formed a small but growing scientific team that will be officially opened in 2014 and will be developed throughout the Asia Pacific region. Cooperation.
Source: Bio Valley
We're Professional Supplier Extract Powder manufacturers and suppliers in China specialized in providing high-quality products at low price. We warmly welcome you to buy or wholesale bulk Supplier Extract Powder for sale here from our factory. For a free sample, contact us now.
Supplier Extract Powder,Supplier Extract ,Supplier Powder Manufacturer in China
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.bodybuildingoil.com